Massachusetts-based Q32 Bio Inc. (Nasdaq: QTTB) announced a proposed underwritten public offering of common stock and pre-funded warrants targeting USD 200 million in gross proceeds, timed to capitalize on positive Phase II data for its lead autoimmune asset and to fund the program's advance toward pivotal trials. The offering arrives on the same day the company reported that bempikibart (ADX-914) met its pre-specified primary endpoint in the 36-week SIGNAL-AA Part B study in severe alopecia areata — a result that materially changes the near-term development calculus for the asset and the capital requirements to pursue it.
The base offering targets USD 200 million, with underwriters granted a 30-day option to purchase up to an additional USD 30 million in common stock, bringing potential total gross proceeds to USD 230 million. Q32 Bio intends to use net proceeds for working capital, research, clinical development, and commercialization efforts, with explicit reference to advancing bempikibart into future clinical trials.
The USD 200 million raise represents a substantial step-up from Q32 Bio's two most recent financings. In May 2026, the company closed a USD 55 million private placement led by BVF Partners, with participation from RA Capital Management, OrbiMed, and Atlas Venture, priced at USD 8.00 per share. Before that, in February 2026, Q32 Bio completed a USD 10.5 million registered direct offering at USD 3.90 per share to bridge near-term clinical operations. As of March 31, 2026, the company held approximately USD 50.8 million in cash, with management previously guiding that combined resources — including guaranteed milestone payments from the December 2025 sale of ADX-097 to Akebia Therapeutics and ATM program proceeds — were sufficient to fund operations into the first half of 2028. The USD 200 million offering, if completed, would substantially extend that runway and provide the capital base required to plan and initiate a Phase III program.
Bempikibart is a fully human anti-IL-7Rα monoclonal antibody that blocks signaling by both IL-7 and TSLP, cytokines implicated in driving T cell-mediated autoimmune pathology. In the SIGNAL-AA Phase IIa Part B study — an open-label, multicenter trial enrolling 33 patients with severe or very severe alopecia areata — bempikibart demonstrated a mean 35.3% reduction in SALT score from baseline at Week 36, with 40% of patients achieving a SALT-20 response (≥80% hair coverage) and 44% achieving SALT-30 and SALT-50 responses. Early signals of durable off-drug responses were also reported. The company holds FDA Fast Track designation for bempikibart in alopecia areata, and the Part B open-label extension is actively enrolling, with longer-term durability data to follow. Alopecia areata affects approximately 700,000 people in the US, with limited approved systemic options; the JAK inhibitor class — including baricitinib and ritlecitinib — currently represents the primary approved treatment category, providing a competitive reference point for any future commercial positioning of bempikibart.